GLP-1 Market
LLY $1183.46 ▲ +0.1% NVO $38.80 ▲ +0.5% PFE $28.67 ▲ +0.9% VKTX $35.56 ▼ -3.2% KLRA $11.21 ▼ -6.4% GPCR $35.93 ▼ -0.2% RHHBY $54.41 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Bortezomib

Company
Janssen Research & Development, LLC
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
42 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

42 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 26, 2026

Find a Clinical Trial Near Me

See recruiting studies for Bortezomib and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02343042

    Selinexor and Backbone Treatments of Multiple Myeloma Patients

    Not yet reported, Not yet reported Karyopharm Therapeutics Inc 300 participants Est. completion 2027-04 25 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT03136146

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

    Not yet reported M.D. Anderson Cancer Center 42 participants Est. completion 2027-08-01 1 site Stand-alone
    Other conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT03590171

    International Study for Treatment of High Risk Childhood Relapsed ALL 2010

    Not yet reported Charite University, Berlin, Germany 250 participants Est. completion 2027-12-31 15 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia (ALL)
    View official trial listing →
  • Recruiting NCT NCT03844360

    Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

    Not yet reported Wei Zhao 1500 participants Est. completion 2026-12-31 2 sites Stand-alone
    Other conditions: Hematological Neoplasms
    View official trial listing →
  • Recruiting NCT NCT03850366

    HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

    Not yet reported Henry Ford Health System 15 participants Est. completion 2028-01-01 1 site Stand-alone
    Other conditions: Hematological Malignancy
    View official trial listing →
  • Recruiting NCT NCT04025450

    Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 50 participants Est. completion 2029-07-15 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT04068597

    Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

    Not yet reported, Not yet reported CellCentric Ltd. 250 participants Est. completion 2027-03-31 39 sites Stand-alone
    Other conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04265872

    Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

    Not yet reported Baylor Research Institute 20 participants Est. completion 2027-03-31 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04268199

    A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

    Not yet reported AHS Cancer Control Alberta 100 participants Est. completion 2026-12 2 sites
    Other conditions: Myeloma, Myeloma Multiple
    View official trial listing →
  • Recruiting NCT NCT04414475

    A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

    Not yet reported Karyopharm Therapeutics Inc 127 participants Est. completion 2028-01 16 sites Stand-alone
    Other conditions: Multiple Myeloma, Refractory
    View official trial listing →
  • Recruiting NCT NCT05272826

    Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

    Not yet reported Canadian Myeloma Research Group 75 participants Est. completion 2031-03 7 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05519085

    A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Not yet reported Celgene 810 participants Est. completion 2033-11-30 266 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05561387

    Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

    Not yet reported SWOG Cancer Research Network 510 participants Est. completion 2031-05-30 397 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Recruiting NCT NCT05695508

    GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

    Not yet reported University of Heidelberg Medical Center 160 participants Est. completion 2029-09-15 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05979363

    A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 20 participants Est. completion 2028-07-01 1 site Stand-alone
    Other conditions: Plasma Cell Leukemia
    View official trial listing →
  • Recruiting NCT NCT06022939

    Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

    Not yet reported SWOG Cancer Research Network 338 participants Est. completion 2030-10-29 117 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06034561

    Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

    Not yet reported Instituto do Cancer do Estado de São Paulo 50 participants Est. completion 2029-08 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
    View official trial listing →
  • Recruiting NCT NCT06039735

    Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma

    Qilu Hospital of Shandong University 50 participants Est. completion 2028-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06083922

    A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

    Not yet reported Memorial Sloan Kettering Cancer Center 20 participants Est. completion 2026-10 11 sites Stand-alone
    Other conditions: Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
    View official trial listing →
  • Recruiting NCT NCT06140966

    Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

    Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 54 participants Est. completion 2027-10-20 1 site Stand-alone
    Other conditions: Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06158269

    DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 40 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06245629

    Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

    Uppsala University 100 participants Est. completion 2025-11-30 1 site
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Recruiting NCT NCT06284395

    Two Schemes Response in Multiple Myeloma

    Hospital General de Mexico 83 participants Est. completion 2024-10-30 1 site
    Other conditions: Response, Acute Phase, Survivorship
    View official trial listing →
  • Recruiting NCT NCT06342466

    Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

    Not yet reported Jin Lu, MD 40 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Systemic Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06463717

    Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

    First Affiliated Hospital of Zhejiang University 210 participants Est. completion 2028-12 1 site
    Other conditions: Multiple Myeloma, Minimal Residual Disease
    View official trial listing →
  • Recruiting NCT NCT06497738

    A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma

    The First Affiliated Hospital with Nanjing Medical University 112 participants Est. completion 2027-06-01 6 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06505369

    Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

    Not yet reported North Estonia Medical Centre 50 participants Est. completion 2028-10 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06627309

    Rapid dFLC Response Predict CHR in AL Amyloidosis

    Peking University People's Hospital 50 participants Est. completion 2026-12-31 8 sites
    Other conditions: Systemic AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06636552

    An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

    Not yet reported Hellenic Society of Hematology 43 participants Est. completion 2029-01-05 7 sites
    Other conditions: Primary Plasma Cell Leukemia
    View official trial listing →
  • Recruiting NCT NCT06682156

    Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

    The First Affiliated Hospital of Soochow University 50 participants Est. completion 2028-06-30 1 site
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06933277

    Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients

    Gruppo Italiano Malattie EMatologiche dell'Adulto 159 participants Est. completion 2028-08 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07008638

    Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

    Not yet reported, Not yet reported Masonic Cancer Center, University of Minnesota 32 participants Est. completion 2028-01-27 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, TP53
    View official trial listing →
  • Recruiting NCT NCT07051850

    Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

    Sung-Soo Park 174 participants Est. completion 2025-12-31 1 site
    Other conditions: Multiple Myeloma, Relapsed, Multiple Myeloma (MM)
    View official trial listing →
  • Recruiting NCT NCT07149857

    A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

    Not yet reported Janssen Research & Development, LLC 60 participants Est. completion 2029-04-06 20 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07222761

    A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported Regeneron Pharmaceuticals 915 participants Est. completion 2034-08-23 24 sites Stand-alone
    Other conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)
    View official trial listing →
  • Recruiting NCT NCT07227311

    A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

    Not yet reported GlaxoSmithKline 200 participants Est. completion 2030-08-30 59 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07285239

    Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

    Not yet reported PrECOG, LLC. 500 participants Est. completion 2034-06 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07297329

    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not yet reported Sinocelltech Ltd. 292 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Multiple Myeloma (MM)
    View official trial listing →
  • Recruiting NCT NCT07513129

    Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

    Not yet reported M.D. Anderson Cancer Center 18 participants Est. completion 2031-12-31 1 site Stand-alone
    Other conditions: T-cell Acute Lymphoblastic Leukemia, Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07579234

    A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Shandong New Time Pharmaceutical Co., LTD 261 participants Est. completion 2029-01-25 1 site
    Other conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
    View official trial listing →
  • Recruiting NCT NCT07623798

    A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

    Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 255 participants Est. completion 2029-12-31 1 site
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07665450

    A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

    Not yet reported Janssen Research & Development, LLC 1000 participants Est. completion 2035-02-02 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00004002

    PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

    Not yet reported NYU Langone Health 5 sites
    Other conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00006098

    PS-341 in Treating Patients With Hematologic Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center Est. completion 2001-10 1 site
    Other conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
    View official trial listing →
  • Terminated NCT NCT00006773

    Bortezomib in Treating Patients With Recurrent Glioma

    Not yet reported National Cancer Institute (NCI) 42 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Recurrent Adult Brain Tumor
    View official trial listing →
  • Completed NCT NCT00017199

    PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

    Not yet reported Ohio State University Comprehensive Cancer Center Est. completion 2007-05 2 sites
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
    View official trial listing →
  • Completed NCT NCT00017329

    PS-341 in Treating Patients With Metastatic Kidney Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 1 site
    Other conditions: Kidney Cancer
    View official trial listing →
  • Completed NCT NCT00023712

    Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

    Not yet reported National Cancer Institute (NCI) 58 participants Est. completion 2010-01 1 site Stand-alone
    Other conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
    View official trial listing →
  • Completed NCT NCT00023855

    PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors

    Not yet reported University of Wisconsin, Madison 1 site
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Terminated NCT NCT00023881

    Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

    Not yet reported M.D. Anderson Cancer Center 7 participants Est. completion 2005-03 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00025376

    PS-341 in Treating Patients With Metastatic Kidney Cancer

    Not yet reported University of Chicago 23 participants Est. completion 2006-03 10 sites
    Other conditions: Kidney Cancer
    View official trial listing →
  • Completed NCT NCT00025584

    PS-341 in Treating Women With Metastatic Breast Cancer

    Not yet reported National Cancer Institute (NCI) 35 participants 1 site Stand-alone
    Other conditions: Recurrent Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Completed NCT NCT00027898

    Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

    Not yet reported National Cancer Institute (NCI) 27 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00028587

    PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

    Not yet reported National Cancer Institute (NCI) 96 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00028639

    PS-341 in Treating Women With Metastatic Breast Cancer

    Not yet reported Northwestern University Est. completion 2003-11 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00030368

    Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

    Not yet reported National Cancer Institute (NCI) 45 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00030875

    Bortezomib in Treating Patients With Mantle Cell Lymphoma

    Not yet reported NCIC Clinical Trials Group 30 participants Est. completion 2009-12-21 10 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00038571

    Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

    Not yet reported M.D. Anderson Cancer Center 60 participants Est. completion 2005-03 1 site Stand-alone
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Terminated NCT NCT00040768

    Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 35 participants 1 site Stand-alone
    Other conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00045695

    Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

    Not yet reported NCIC Clinical Trials Group 27 participants Est. completion 2009-12 12 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00049088

    Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors

    Not yet reported National Cancer Institute (NCI) 24 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00051974

    Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

    Not yet reported Millennium Pharmaceuticals, Inc. 155 participants 20 sites
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00052338

    Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 34 participants 1 site Stand-alone
    Other conditions: Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00052507

    Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer

    Not yet reported University Health Network, Toronto 4 sites
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT00052689

    Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

    Not yet reported National Cancer Institute (NCI) 88 participants 1 site Stand-alone
    Other conditions: Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT00063726

    A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

    Not yet reported Millennium Pharmaceuticals, Inc. 600 participants Est. completion 2005-07 76 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • No Longer Available NCT NCT00063791

    A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

    Millennium Pharmaceuticals, Inc. 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00064636

    Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

    Not yet reported Millennium Pharmaceuticals, Inc. 46 participants
    Other conditions: Advanced Non-Small Cell Lung Cancer, Other Solid Tumors
    View official trial listing →
  • Terminated NCT NCT00066625

    Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

    Not yet reported National Cancer Institute (NCI) 30 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00068289

    Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

    Not yet reported SWOG Cancer Research Network Est. completion 2007-07 91 sites
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00068484

    A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

    Not yet reported National Cancer Institute (NCI) 25 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00072150

    Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

    Not yet reported National Cancer Institute (NCI) 40 participants 1 site Stand-alone
    Other conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer
    View official trial listing →
  • Completed NCT NCT00074009

    Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

    Not yet reported Memorial Sloan Kettering Cancer Center 4 sites
    Other conditions: Gastric Cancer
    View official trial listing →
  • Completed NCT NCT00075881

    Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 44 participants Est. completion 2012-10 1 site Stand-alone
    Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00080405

    Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 40 participants
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00081939

    UARK 2003-33, Total Therapy III

    Not yet reported University of Arkansas 303 participants Est. completion 2014-09 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00082784

    Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

    Not yet reported National Cancer Institute (NCI) 93 participants Est. completion 2014-09 5 sites Stand-alone
    Obstructive sleep apnea Other conditions: Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Plasma Cell Myeloma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00084747

    Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

    Not yet reported, Not yet reported Jonsson Comprehensive Cancer Center 30 participants Est. completion 2013-01 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Terminated NCT NCT00085410

    Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

    Not yet reported National Cancer Institute (NCI) 20 participants Est. completion 2010-04 1 site Stand-alone
    Other conditions: Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
    View official trial listing →
  • Completed NCT NCT00091117

    Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

    Not yet reported National Cancer Institute (NCI) 80 participants 3 sites Stand-alone
    Other conditions: Hepatic Complications, Malignant Neoplasm
    View official trial listing →
  • Completed NCT NCT00093756

    Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

    Not yet reported, Not yet reported National Cancer Institute (NCI) 52 participants Est. completion 2013-05 143 sites Stand-alone
    Other conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00095680

    Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

    Not yet reported Scios, Inc. 30 participants Est. completion 2006-02
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00098982

    Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 16 participants 3 sites
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT00103259

    Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    Not yet reported National Cancer Institute (NCI) 71 participants Est. completion 2011-11 1 site Stand-alone
    Other conditions: Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
    View official trial listing →
  • Terminated NCT NCT00103272

    17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

    Not yet reported National Cancer Institute (NCI) 74 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT00103376

    Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

    Not yet reported Medical University of South Carolina 23 participants Est. completion 2011-06 4 sites
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00104871

    Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

    Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2014-04 9 sites Stand-alone
    Other conditions: Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
    View official trial listing →
  • Terminated NCT NCT00106262

    Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

    Not yet reported Women and Infants Hospital of Rhode Island 38 participants Est. completion 2007-03 1 site
    Other conditions: Cervical Cancer
    View official trial listing →
  • Completed NCT NCT00111319

    VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00111748

    UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

    Not yet reported University of Arkansas 180 participants Est. completion 2006-09 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00116961

    Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

    Not yet reported University of Michigan Rogel Cancer Center 40 participants Est. completion 2007-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00117351

    VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

    Not yet reported Millennium Pharmaceuticals, Inc. Est. completion 2007-07 1 site
    Other conditions: Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Bronchiolo-Alveolar
    View official trial listing →
  • Completed NCT NCT00118183

    Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 62 participants 1 site Stand-alone
    Other conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00135187

    Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

    Not yet reported University of Michigan Rogel Cancer Center 30 participants Est. completion 2007-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00153920

    Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 66 participants Est. completion 2008-09 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00153933

    Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 58 participants Est. completion 2014-07 6 sites Stand-alone
    Other conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00169468

    Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

    Not yet reported Lymphoma Study Association 48 participants Est. completion 2006-01 4 sites
    Other conditions: B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00193232

    Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

    Not yet reported SCRI Development Innovations, LLC 50 participants Est. completion 2007-02
    Other conditions: Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT00200382

    Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

    Not yet reported Rasim Gucalp 27 participants Est. completion 2007-05 5 sites
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00200681

    IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma

    Not yet reported Nantes University Hospital 493 participants Est. completion 2008-06 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00210327

    VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

    Not yet reported International Extranodal Lymphoma Study Group (IELSG) 33 participants Est. completion 2009-04 1 site
    Obstructive sleep apnea
    View official trial listing →
  • Terminated NCT NCT00210392

    VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

    Not yet reported International Extranodal Lymphoma Study Group (IELSG) 12 participants Est. completion 2007-11 1 site
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT00216697

    An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

    Not yet reported Janssen Pharmaceutical K.K. 13 participants Est. completion 2006-10
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00243035

    Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 64 participants 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00256776

    MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

    Not yet reported European Society for Blood and Marrow Transplantation 269 participants Est. completion 2015-12 81 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00262860

    Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Not yet reported University of Rochester 18 participants 2 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00262873

    Bortezomib in Treating Patients With Myelodysplastic Syndromes

    Not yet reported University of Rochester 8 participants Est. completion 2010-10 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes
    View official trial listing →
  • Terminated NCT NCT00265928

    Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Not yet reported University of Virginia 46 participants 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00271804

    Study of Velcade and Thalidomide in Patients With Myelodysplasia

    Not yet reported Massachusetts General Hospital 28 participants Est. completion 2007-04 3 sites
    Other conditions: Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00276614

    Bortezomib in Treating Patients With Metastatic Kidney Cancer

    Not yet reported Jonsson Comprehensive Cancer Center 4 participants Est. completion 2009-07 1 site Stand-alone
    Other conditions: Kidney Cancer
    View official trial listing →
  • Completed NCT NCT00287872

    Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 30 participants Est. completion 2010-11 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00290680

    Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors

    Not yet reported Medical University of South Carolina 36 participants Est. completion 2009-01 1 site
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Terminated NCT NCT00290706

    A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

    Not yet reported, Not yet reported Northwestern University 32 participants Est. completion 2012-09-05 3 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00291538

    Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma

    Not yet reported Nantes University Hospital 20 participants Est. completion 2008-10 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00295932

    Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 79 participants Est. completion 2018-03-11 8 sites Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00298766

    Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

    Not yet reported, Not yet reported Millennium Pharmaceuticals, Inc. 70 participants Est. completion 2009-09 4 sites
    Other conditions: Amyloidosis
    View official trial listing →
  • Completed NCT NCT00303797

    Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

    Not yet reported National Cancer Institute (NCI) 50 participants 1 site Stand-alone
    Other conditions: Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00305734

    Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer

    Not yet reported National Cancer Institute (NCI) 50 participants 1 site Stand-alone
    Other conditions: Recurrent Nasopharyngeal Cancer, Stage IV Nasopharyngeal Cancer
    View official trial listing →
  • Completed NCT NCT00307086

    Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 30 participants Est. completion 2012-03 1 site
    Other conditions: Multiple Myeloma, Plasma Cell Leukemia
    View official trial listing →
  • Completed NCT NCT00310037

    Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

    Not yet reported Alliance for Clinical Trials in Oncology 151 participants Est. completion 2022-06 48 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT00313690

    Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer

    Not yet reported, Not yet reported University of Southern California
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00315757

    Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

    Not yet reported Human Genome Sciences Inc. 105 participants Est. completion 2010-10 20 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00334438

    Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

    Not yet reported UNC Lineberger Comprehensive Cancer Center 12 participants Est. completion 2011-10 2 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00334932

    Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

    Not yet reported, Not yet reported Herbert Irving Comprehensive Cancer Center 32 participants 2 sites
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00348985

    PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

    Not yet reported National Cancer Institute (NCI) 55 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT00352742

    A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

    Not yet reported, Not yet reported Attenuon 46 participants Est. completion 2008-12 10 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00358020

    Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients

    Not yet reported University of Turin, Italy 30 participants Est. completion 2008-12 7 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00361088

    A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

    Not yet reported, Not yet reported H. Lee Moffitt Cancer Center and Research Institute 42 participants Est. completion 2007-06 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00362882

    Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 81 participants Est. completion 2010-07 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT00372905

    Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

    Not yet reported, Not yet reported Northwestern University 18 participants Est. completion 2013-07-08 2 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00373906

    Velcade in MALT Lymphoma Patients

    Not yet reported Medical University of Vienna 16 participants
    Other conditions: MALT Lymphoma
    View official trial listing →
  • Completed NCT NCT00374699

    Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas

    Not yet reported, Not yet reported Samsung Medical Center 55 participants Est. completion 2009-10 1 site
    Other conditions: Peripheral T-Cell Lymphomas, Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00376961

    S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported SWOG Cancer Research Network 68 participants Est. completion 2017-09 147 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00377052

    Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

    Not yet reported NCIC Clinical Trials Group 29 participants Est. completion 2011-06-21 11 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00378209

    Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 65 participants Est. completion 2016-10 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00381940

    Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

    Not yet reported National Cancer Institute (NCI) 26 participants Est. completion 2016-12-31 1 site Stand-alone
    Other conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Lymphocyte Predominant Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00383474

    Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

    Not yet reported National Cancer Institute (NCI) 35 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Blastic Phase, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Disease, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00388635

    Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.

    Not yet reported, Not yet reported PETHEMA Foundation 60 participants Est. completion 2008-12 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00391157

    VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma

    Not yet reported PETHEMA Foundation 40 participants Est. completion 2008-01 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00407303

    Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

    Not yet reported, Not yet reported Gemin X 24 participants Est. completion 2009-11 5 sites Stand-alone
    Other conditions: Mantle-Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT00413959

    VELCADE,Rituximab,Cyclophosphamide and Decadron

    Not yet reported Oncology Specialists, S.C. 12 participants Est. completion 2011-01 2 sites
    Other conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
    View official trial listing →
  • Completed NCT NCT00416273

    A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma

    Not yet reported Janssen-Cilag G.m.b.H 217 participants Est. completion 2013-05 38 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00424840

    Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

    Not yet reported University of Massachusetts, Worcester 12 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00425503

    PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

    Not yet reported Baylor College of Medicine 40 participants Est. completion 2013-12 1 site
    Other conditions: Prostate Neoplasms
    View official trial listing →
  • Completed NCT NCT00425750

    Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

    Not yet reported Vanderbilt-Ingram Cancer Center 25 participants Est. completion 2009-06 7 sites Stand-alone
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT00426855

    Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

    Not yet reported, Not yet reported Peter Moosmann 12 participants Est. completion 2009-06 Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT00428142

    Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

    Not yet reported NCIC Clinical Trials Group 95 participants Est. completion 2012-01-06 19 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00438841

    Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

    Not yet reported Fred Hutchinson Cancer Center 43 participants 10 sites
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00439361

    Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

    Not yet reported M.D. Anderson Cancer Center 14 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Hodgkin Lymphoma, Lymphoma
    View official trial listing →
  • Terminated NCT NCT00440076

    Velcade in Myelodysplastic Syndrome - Pilot Study

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 28 participants Est. completion 2008-03 4 sites
    Other conditions: MDS
    View official trial listing →
  • Completed NCT NCT00440635

    Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma

    Janssen-Cilag International NV 641 participants Est. completion 2006-10
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00440726

    Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

    Not yet reported, Not yet reported Therapeutic Advances in Childhood Leukemia Consortium 31 participants Est. completion 2011-02-26 24 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT00440765

    VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

    Janssen-Cilag B.V. 331 participants Est. completion 2012-01 44 sites
    Other conditions: Multiple Myeloma, Hematological Neoplasms
    View official trial listing →
  • Terminated NCT NCT00441168

    Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

    Not yet reported Janssen-Cilag International NV 30 participants Est. completion 2008-01 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00458913

    Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 82 participants Est. completion 2012-03 1 site
    Other conditions: Malignant Mesothelioma
    View official trial listing →
  • Completed NCT NCT00477412

    Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 107 participants Est. completion 2020-10-28 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT00479167

    A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

    Not yet reported Rush University Medical Center 1 participants Est. completion 2008-09 1 site Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00483262

    Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 63 participants Est. completion 2012-02 3 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT00492050

    Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

    Not yet reported M.D. Anderson Cancer Center 46 participants Est. completion 2026-06-28 1 site Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00500422

    Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

    Not yet reported M.D. Anderson Cancer Center 134 participants Est. completion 2012-11 1 site
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT00504634

    Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma

    Not yet reported M.D. Anderson Cancer Center 8 participants Est. completion 2010-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00507416

    Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

    Not yet reported Millennium Pharmaceuticals, Inc. 502 participants Est. completion 2013-03 235 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00510887

    Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

    Not yet reported Duke University 14 participants Est. completion 2013-09 1 site Stand-alone
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Completed NCT NCT00511069

    Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia

    Not yet reported University of Bologna 3 participants Est. completion 2008-02 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00513877

    Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

    Not yet reported Cancer Trials Ireland 33 participants 13 sites Stand-alone
    Other conditions: Malignant Mesothelioma
    View official trial listing →
  • Completed NCT NCT00513955

    Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported University Hospital Plymouth NHS Trust 50 participants Est. completion 2014-10 25 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00514371

    A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

    Not yet reported, Not yet reported Bristol-Myers Squibb 22 participants Est. completion 2009-02 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00523848

    Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

    Not yet reported Roswell Park Cancer Institute 46 participants Est. completion 2012-10 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00531453

    A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 98 participants Est. completion 2009-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00532389

    Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

    Not yet reported Novartis Pharmaceuticals 62 participants Est. completion 2013-10 16 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00538187

    Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) 18 participants 1 site Stand-alone
    Other conditions: Adult Non-Hodgkin Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT00546780

    A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

    Not yet reported Bristol-Myers Squibb 31 participants Est. completion 2010-03 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00547534

    Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

    Not yet reported University of Rochester 31 participants Est. completion 2009-10 3 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT00548717

    Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

    Not yet reported Dana-Farber Cancer Institute 15 participants Est. completion 2013-09 1 site Stand-alone
    Other conditions: Graft-vs-Host Disease
    View official trial listing →
  • Terminated NCT NCT00560352

    Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

    Not yet reported Bristol-Myers Squibb 16 participants Est. completion 2011-02 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00561743

    A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

    Not yet reported Janssen-Ortho Inc., Canada 50 participants Est. completion 2007-05
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00569868

    UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported University of Arkansas 11 participants Est. completion 2008-01 1 site
    Other conditions: MULTIPLE MYELOMA
    View official trial listing →
  • Completed NCT NCT00570180

    Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma

    Not yet reported University Health Network, Toronto 36 participants Est. completion 2015-09-15 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00571493

    VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma

    Not yet reported, Not yet reported University of Nebraska 42 participants Est. completion 2014-11-01 1 site Stand-alone
    Other conditions: Non-hodgkin's Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT00572169

    UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

    Not yet reported University of Arkansas 177 participants Est. completion 2027-08 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00573391

    Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

    Not yet reported University of Arkansas 5 participants Est. completion 2008-07 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT00577668

    A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)

    Not yet reported University of Arkansas Est. completion 2009-04 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00580242

    A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

    Not yet reported Massachusetts General Hospital 23 participants Est. completion 2012-03 2 sites Stand-alone
    Other conditions: Myelodysplasia
    View official trial listing →
  • Completed NCT NCT00580320

    Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

    Not yet reported Virginia Commonwealth University 17 participants Est. completion 2013-11 2 sites Stand-alone
    Other conditions: Melanoma, Soft Tissue Sarcoma, Parathyroid Carcinoma, Small Cell Carcinoma of the Lung, Carcinoid Tumors
    View official trial listing →
  • Completed NCT NCT00581360

    Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck

    Not yet reported University of Pittsburgh 10 participants Est. completion 2011-06 21 sites
    Other conditions: Adenoid Cystic Carcinoma
    View official trial listing →
  • Completed NCT NCT00581919

    Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

    Not yet reported University of Wisconsin, Madison 32 participants Est. completion 2013-07 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00590603

    Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Duke University 25 participants Est. completion 2012-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00609817

    Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

    Not yet reported La Jolla Pharmaceutical Company 9 participants Est. completion 2009-04 3 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT00610792

    Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

    Not yet reported Millennium Pharmaceuticals, Inc. 91 participants 7 sites Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT00622674

    Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

    Not yet reported Masonic Cancer Center, University of Minnesota 37 participants Est. completion 2010-02 1 site Stand-alone
    Other conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00624936

    Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

    Not yet reported Ohio State University Comprehensive Cancer Center 23 participants Est. completion 2014-06 1 site
    Other conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
    View official trial listing →
  • Completed NCT NCT00633594

    Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

    Not yet reported, Not yet reported SCRI Development Innovations, LLC 39 participants Est. completion 2016-11 7 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00634179

    A Phase I/II Trial of VR-CHOP in Lymphoma Patients

    Not yet reported, Not yet reported Emory University 37 participants Est. completion 2015-11 1 site Stand-alone
    Other conditions: Lymphoma, B-Cell, Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00636311

    A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma

    Not yet reported Istituto Clinico Humanitas 13 participants Est. completion 2010-02 1 site Stand-alone
    Other conditions: Hodgkin Disease
    View official trial listing →
  • Completed NCT NCT00636792

    A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

    Not yet reported Millennium Pharmaceuticals, Inc. 73 participants Est. completion 2010-05 2 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00641706

    Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme

    Not yet reported National Cancer Institute (NCI) 44 participants Est. completion 2010-11 214 sites Stand-alone
    Obstructive sleep apnea Other conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Recurrent Adult Brain Tumor
    View official trial listing →
  • Completed NCT NCT00644696

    Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

    Not yet reported University of Michigan Rogel Cancer Center 18 participants Est. completion 2012-07 1 site Stand-alone
    Other conditions: Neuroblastoma
    View official trial listing →
  • Completed NCT NCT00664898

    A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Genentech, Inc. 18 participants Est. completion 2010-04-08 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00666588

    Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

    Not yet reported National Cancer Institute (NCI) 52 participants Est. completion 2012-12 82 sites Stand-alone
    Other conditions: Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myelomonocytic Leukemia (M4), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00667641

    Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

    Not yet reported University of Medicine and Dentistry of New Jersey 16 participants Est. completion 2009-02 1 site
    Other conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00670423

    A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation

    Not yet reported Jennifer E. Schwartz 27 participants Est. completion 2013-10-16 1 site
    Other conditions: Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation, Transplantation, Homologous
    View official trial listing →
  • Completed NCT NCT00670631

    Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment

    Not yet reported Guido Tricot 46 participants Est. completion 2014-04 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00691704

    Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

    Not yet reported Cristina Gasparetto 18 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00702052

    Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

    Not yet reported Novartis Pharmaceuticals 58 participants Est. completion 2012-04-20 31 sites
    Other conditions: Lymphoma, Mantle- Cell
    View official trial listing →
  • Completed NCT NCT00722722

    The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates

    Not yet reported Mayo Clinic 18 participants Est. completion 2014-04 1 site
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Withdrawn NCT NCT00723658

    S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

    Not yet reported SWOG Cancer Research Network 29 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00724568

    Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

    Not yet reported, Not yet reported University of Michigan Rogel Cancer Center 74 participants Est. completion 2014-09-03 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00731952

    Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer

    Not yet reported University of Virginia 21 participants Est. completion 2014-03 1 site
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT00734877

    UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

    Not yet reported University of Arkansas 382 participants Est. completion 2028-09 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00750815

    Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

    Not yet reported, Not yet reported H. Lee Moffitt Cancer Center and Research Institute 58 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00765102

    Trial of Romidepsin and Bortezomib for Multiple Myeloma

    Not yet reported Celgene 32 participants Est. completion 2010-03-01 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00773747

    Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

    Not yet reported Merck Sharp & Dohme LLC 637 participants Est. completion 2015-06-30 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00782821

    Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

    Not yet reported University of Cincinnati 40 participants Est. completion 2013-03 2 sites
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00789256

    Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

    Not yet reported Dartmouth-Hitchcock Medical Center 26 participants Est. completion 2008-12 2 sites Stand-alone
    Other conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00791011

    Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

    Not yet reported Amgen 33 participants Est. completion 2011-08 Stand-alone
    Other conditions: Hodgkin's Lymphoma, Low Grade Lymphoma, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00793572

    Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

    Not yet reported Fred Hutchinson Cancer Center 32 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT00793650

    Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

    Not yet reported, Not yet reported Emory University 39 participants Est. completion 2011-09 1 site
    Other conditions: Cancer, Multiple Myeloma
    View official trial listing →
  • No Longer Available NCT NCT00799539

    A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

    Janssen-Ortho Inc., Canada 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00814541

    PAD. ICORG 05-01, V11

    Not yet reported Cancer Trials Ireland 53 participants Est. completion 2012-12 9 sites Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00815919

    Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

    Not yet reported Dana-Farber Cancer Institute 22 participants Est. completion 2013-01 1 site Stand-alone
    Other conditions: Chronic Graft Versus Host Disease
    View official trial listing →
  • Terminated NCT NCT00818649

    Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

    Not yet reported Masonic Cancer Center, University of Minnesota 16 participants Est. completion 2012-05 1 site Stand-alone
    Other conditions: Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Withdrawn NCT NCT00837174

    Relapsed and/or Refractory Non-Hodgkin Lymphoma Study

    Not yet reported The Methodist Hospital Research Institute Est. completion 2012-05 Stand-alone
    Other conditions: Non-Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT00849251

    Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

    Not yet reported, Not yet reported University of Washington 31 participants Est. completion 2015-06 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00850499

    Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

    Not yet reported Millennium Pharmaceuticals, Inc. 12 participants Est. completion 2011-10 43 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00858234

    Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

    Not yet reported Merck Sharp & Dohme LLC 9 participants Est. completion 2012-04-19 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT00869232

    UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

    Not yet reported University of Arkansas 90 participants Est. completion 2028-10 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00872521

    A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma

    Not yet reported Janssen-Cilag Pty Ltd 107 participants Est. completion 2011-11 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00889798

    Tumor Registry of Lymphatic Neoplasia

    iOMEDICO AG 3795 participants Est. completion 2019-08-31
    Other conditions: Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)
    View official trial listing →
  • Completed NCT NCT00901147

    Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

    Not yet reported Singapore General Hospital 25 participants Est. completion 2014-01 5 sites Stand-alone
    Other conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma, Extranodal NK/T-cell Lymphoma Nasal Type, Enteropathy- Type T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative), Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
    View official trial listing →
  • Completed NCT NCT00903734

    An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

    Not yet reported M.D. Anderson Cancer Center 16 participants 1 site
    Other conditions: Advanced Cancers
    View official trial listing →
  • Completed NCT NCT00908232

    Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD

    Not yet reported Janssen-Cilag International NV 163 participants Est. completion 2011-08 42 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00911859

    A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

    Not yet reported Janssen Research & Development, LLC 118 participants Est. completion 2013-04 37 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00920855

    Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Cephalon 40 participants Est. completion 2011-12 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00932698

    Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 60 participants Est. completion 2017-05-23 5 sites
    Other conditions: Relapsed and Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00956033

    Skin Biopsies in Chemotherapy-Induced Neuropathy

    Erasmus Medical Center 26 participants Est. completion 2012-02 1 site
    Other conditions: Multiple Myeloma, Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT00958256

    Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

    Not yet reported M.D. Anderson Cancer Center 22 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma, Lymphoma
    View official trial listing →
  • Completed NCT NCT00963820

    Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 60 participants Est. completion 2014-01 6 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00972959

    Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy

    Not yet reported University of Athens 17 participants Est. completion 2013-05 3 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00980395

    Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

    Not yet reported University of Arizona 24 participants Est. completion 2018-08-14 1 site Stand-alone
    Other conditions: Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, SLL
    View official trial listing →
  • Terminated NCT NCT00985907

    Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported University of California, San Francisco 13 participants Est. completion 2010-01-12 2 sites Stand-alone
    Other conditions: Multiple Myeloma, Patient Participation
    View official trial listing →
  • Completed NCT NCT01000285

    EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

    Not yet reported, Not yet reported Washington University School of Medicine 18 participants Est. completion 2016-04 6 sites Stand-alone
    Other conditions: Leukemia-Lymphoma, Adult T-Cell
    View official trial listing →
  • Completed NCT NCT01009840

    IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 30 participants Est. completion 2012-03-01 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01016028

    Chemotherapy-Induced Peripheral Neuropathy Survey

    M.D. Anderson Cancer Center Est. completion 2013-02
    Other conditions: Breast Cancer, Colorectal Cancer, Myeloma, Chemotherapy-induced Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT01016730

    Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

    Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2015-01-07 9 sites Stand-alone
    Other conditions: AIDS-Related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma
    View official trial listing →
  • Completed NCT NCT01021592

    Quality of Life in Multiple Myeloma Patients Treated With Bortezomib

    Janssen Korea, Ltd., Korea 140 participants Est. completion 2008-07
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01023308

    Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

    Not yet reported Novartis Pharmaceuticals 767 participants Est. completion 2015-07-30 210 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01026701

    Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.

    Janssen Korea, Ltd., Korea 104 participants Est. completion 2009-11
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01029730

    Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

    Not yet reported SCRI Development Innovations, LLC 55 participants Est. completion 2016-07 20 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT01030302

    A Retreatment Study With Bortezomib for Multiple Myeloma

    Janssen Korea, Ltd., Korea 56 participants Est. completion 2010-09
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01046006

    Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia

    Not yet reported Meletios A. Dimopoulos 59 participants Est. completion 2015-11 4 sites Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT01053949

    IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma

    Not yet reported University Hospital, Lille 84 participants Est. completion 2015-04 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01055301

    S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported SWOG Cancer Research Network Est. completion 2011-07 21 sites Stand-alone
    Other conditions: Multiple Myeloma, Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT01056276

    Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

    Not yet reported SCRI Development Innovations, LLC 59 participants Est. completion 2017-02 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01056601

    Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

    Not yet reported Masonic Cancer Center, University of Minnesota 7 participants Est. completion 2011-02 1 site Stand-alone
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT01058239

    Bortezomib Plus Rituximab for EBV+ PTLD

    Not yet reported Massachusetts General Hospital 7 participants Est. completion 2017-11 3 sites Stand-alone
    Other conditions: Post-transplant Lymphoproliferative Disease, Solid Organ Transplant, Stem Cell Transplant (Bone Marrow Transplant), Epstein Barr Virus Infections
    View official trial listing →
  • Completed NCT NCT01060202

    Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib

    Janssen Korea, Ltd., Korea 60 participants Est. completion 2011-07
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01063179

    Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

    Not yet reported Fondazione EMN Italy Onlus 511 participants Est. completion 2014-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01063907

    A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Kyowa Kirin Co., Ltd. 95 participants Est. completion 2013-11 26 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01072773

    Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

    Not yet reported Mayo Clinic 2 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Primary Systemic Amyloidosis
    View official trial listing →
  • Terminated NCT NCT01078441

    Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

    Not yet reported National Cancer Institute (NCI) 2 participants Est. completion 2014-03 130 sites Stand-alone
    Other conditions: Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01090921

    Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

    Not yet reported Boston VA Research Institute, Inc. 50 participants Est. completion 2015-03 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01100242

    Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma

    Not yet reported New Mexico Cancer Research Alliance 17 participants Est. completion 2015-02 3 sites Stand-alone
    Other conditions: Metastatic Renal Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT01119794

    Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

    Not yet reported Brown University 10 participants Est. completion 2015-07 3 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkins
    View official trial listing →
  • Completed NCT NCT01127009

    Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported Case Comprehensive Cancer Center 3 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01132911

    A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

    Not yet reported National Cancer Institute (NCI) 5 participants Est. completion 2011-04-13 1 site
    Other conditions: Lymphoma, Sarcoma, WilmsTumor, Neuroblastoma
    View official trial listing →
  • Completed NCT NCT01146834

    Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

    Not yet reported Weill Medical College of Cornell University 47 participants Est. completion 2019-02-04 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01158105

    Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

    Not yet reported Baylor Research Institute 25 participants Est. completion 2017-01 1 site Stand-alone
    Other conditions: Chronic Graft-versus-host Disease
    View official trial listing →
  • Withdrawn NCT NCT01162031

    Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

    Not yet reported Stanford University Est. completion 2011-07 1 site
    Other conditions: Leukemia, Acute Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01163357

    Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

    Not yet reported City of Hope Medical Center 18 participants Est. completion 2024-05-20 1 site Stand-alone
    Other conditions: Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01169857

    Velcade for Proliferative Lupus Nephritis

    Not yet reported The Rogosin Institute Est. completion 2012-12 1 site
    Other conditions: Lupus Nephritis, Proteinuria, Hematuria
    View official trial listing →
  • Status unknown NCT NCT01171443

    The Pathophysiology of Bortezomib Induced Peripheral Neuropathy

    Wolfson Medical Center 30 participants Est. completion 2011-08 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01177683

    Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

    Not yet reported, Not yet reported Sherif Farag, MB, BS 32 participants Est. completion 2017-12 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01191060

    Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years

    Not yet reported University Hospital, Toulouse 700 participants Est. completion 2018-11-30 68 sites Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT01206205

    Frontline Therapy in de Novo Multiple Myeloma Patients Under 65

    Not yet reported University Hospital, Toulouse 31 participants Est. completion 2012-10 9 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01208818

    Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy

    Not yet reported Assistance Publique - Hôpitaux de Paris 284 participants Est. completion 2017-12 1 site Stand-alone
    Other conditions: Chronic Renal Failure With Uremic Nephropathy
    View official trial listing →
  • Completed NCT NCT01212952

    Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Mayo Clinic 50 participants Est. completion 2018-03-22 3 sites Stand-alone
    Other conditions: Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01233895

    Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma

    Not yet reported Sanofi 26 participants Est. completion 2008-09 4 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01236391

    Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

    Not yet reported Pharmacyclics LLC. 115 participants Est. completion 2014-01 18 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01237249

    Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

    Not yet reported PETHEMA Foundation 250 participants Est. completion 2016-05 63 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01241708

    Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

    Not yet reported Hackensack Meridian Health 148 participants Est. completion 2023-07-15 1 site Stand-alone
    Other conditions: Multiple Myeloma, Auto Stem Cell Transplant
    View official trial listing →
  • Completed NCT NCT01255514

    Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

    Not yet reported Yonsei University 30 participants Est. completion 2014-12-31 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01273844

    Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)

    Not yet reported Zhi-Hong Liu, M.D. 21 participants Est. completion 2016-05-12 1 site Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Completed NCT NCT01277016

    A Trial for Systemic Light-chain (AL) Amyloidosis

    Not yet reported European Myeloma Network B.V. 110 participants Est. completion 2016-07-31 1 site Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Completed NCT NCT01281917

    Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

    Not yet reported University of Wisconsin, Madison 40 participants Est. completion 2014-06 18 sites
    Other conditions: Non-Hodgkins Lymphoma
    View official trial listing →
  • Completed NCT NCT01283997

    Prevention of Treatment Induced Neuropathy in Multiple Myeloma

    Not yet reported M.D. Anderson Cancer Center 79 participants Est. completion 2022-08-22 1 site
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT01286077

    Velcade Consolidation Bone Study

    Not yet reported Janssen-Cilag International NV 106 participants Est. completion 2014-04 21 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01309412

    A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Pharmaceutical K.K. 9 participants Est. completion 2012-12 5 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01311687

    A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

    Not yet reported Celgene 455 participants Est. completion 2017-08-29 94 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01313897

    UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma

    Not yet reported University of Arkansas 10 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01322776

    Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma

    Not yet reported, Not yet reported Sun Yat-sen University 40 participants Est. completion 2013-10 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma Recurrent
    View official trial listing →
  • Completed NCT NCT01323920

    Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

    Not yet reported Dana-Farber Cancer Institute 35 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT01324596

    A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib

    Not yet reported University Hospital Southampton NHS Foundation Trust 1132 participants Est. completion 2015-06 109 sites Stand-alone
    Other conditions: Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Completed NCT NCT01324947

    Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

    Not yet reported Celgene 74 participants Est. completion 2014-07-31 91 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01328236

    Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

    Not yet reported Clinical Service, China 20 participants Est. completion 2015-09 1 site Stand-alone
    Other conditions: Plasma Cell Leukemia, Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01329289

    SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

    Not yet reported University of Pittsburgh Est. completion 2012-02 1 site Stand-alone
    Other conditions: Multiple Myeloma in Relapse, Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01332617

    Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

    Not yet reported University of Louisville Est. completion 2019-02 Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT01337752

    Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

    Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2013-05 8 sites Stand-alone
    Other conditions: Multiple Myeloma, Renal Insufficiency
    View official trial listing →
  • Terminated NCT NCT01349595

    Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

    Not yet reported Mark Stegall 4 participants Est. completion 2015-03 1 site Stand-alone
    Other conditions: Disorder of Transplanted Kidney
    View official trial listing →
  • Terminated NCT NCT01350232

    Treatment of Sickle Cell Anemia With Stem Cell Transplant

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 2 participants Est. completion 2011-08 1 site Stand-alone
    Other conditions: Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia
    View official trial listing →
  • Completed NCT NCT01370434

    Two Cycles of PAD Combination by AHCT in MM

    Not yet reported Cooperative Study Group A for Hematology 43 participants Est. completion 2009-01 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01371981

    Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

    Not yet reported National Cancer Institute (NCI) 1645 participants Est. completion 2026-03-31 220 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma
    View official trial listing →
  • Completed NCT NCT01381692

    Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 9 participants Est. completion 2021-09-01 11 sites Stand-alone
    Other conditions: Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Terminated NCT NCT01397591

    Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

    Not yet reported OHSU Knight Cancer Institute 3 participants Est. completion 2013-07 1 site Stand-alone
    Other conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01420926

    Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

    Not yet reported National Cancer Institute (NCI) 165 participants Est. completion 2021-04-01 53 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Therapy-Related Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01435395

    Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

    Not yet reported Emory University 12 participants Est. completion 2016-04 2 sites Stand-alone
    Other conditions: Glioblastoma Multiforme
    View official trial listing →
  • Status unknown NCT NCT01439750

    Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

    Not yet reported Milton S. Hershey Medical Center 13 participants Est. completion 2020-08 2 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01445405

    Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

    Not yet reported National Cancer Institute (NCI) 3 participants Est. completion 2010-08-27 1 site
    Other conditions: Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer, Pharyngeal Cancer
    View official trial listing →
  • Status unknown NCT NCT01449344

    Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL

    Not yet reported Prof. Dr. M. Dreyling (co-chairman) 128 participants Est. completion 2018-12 54 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01453088

    Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

    Not yet reported Hackensack Meridian Health 63 participants Est. completion 2022-05-01 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01457144

    Study of Mantle Cell Lymphoma Treatment by RiBVD

    Not yet reported French Innovative Leukemia Organisation 76 participants Est. completion 2016-03 1 site
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01464112

    A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 18 participants Est. completion 2013-11-19 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01472627

    Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

    Dana-Farber Cancer Institute 11 participants Est. completion 2018-01 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01481194

    ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Vejle Hospital 35 participants Est. completion 2018-08-28 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01484626

    Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

    Not yet reported, Not yet reported Loyola University 3 participants Est. completion 2014-06-18 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01485835

    A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported Emory University 8 participants Est. completion 2015-09 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01492881

    Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported UNC Lineberger Comprehensive Cancer Center Est. completion 2017-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01497093

    Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

    Not yet reported Celgene 34 participants Est. completion 2019-07-23 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01497626

    Lapatinib and Bortezomib in Patients With Advanced Malignancies

    Not yet reported Georgetown University 15 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Terminated NCT NCT01504477

    Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

    Not yet reported, Not yet reported Georgetown University 6 participants Est. completion 2014-02 1 site Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT01521533

    NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

    Not yet reported TME Pharma AG 28 participants Est. completion 2015-09 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01522872

    Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Threshold Pharmaceuticals 98 participants Est. completion 2017-09 10 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01524445

    Retrospective Survey of Re-treatment With Bortezomib

    Janssen Pharmaceutica N.V., Belgium 35 participants Est. completion 2011-10 4 sites
    Other conditions: Hematological Cancer, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01531998

    Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 14 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Terminated NCT NCT01534143

    High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

    Not yet reported Barbara Ann Karmanos Cancer Institute 1 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01539083

    Velcade (Bortezomib) Consolidation After Transplant

    Not yet reported Janssen Scientific Affairs, LLC 256 participants Est. completion 2018-01-09 23 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01548573

    Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

    Not yet reported University of Iowa 19 participants Est. completion 2014-08 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01553357

    Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

    Not yet reported IRCCS Centro di Riferimento Oncologico della Basilicata 23 participants Est. completion 2011-09 1 site
    Other conditions: Primary Plasma Cell Leukemia
    View official trial listing →
  • Terminated NCT NCT01556347

    Multi-Drug Desensitization Protocol for Heart Transplant Candidates

    Not yet reported Providence Health & Services 2 participants Est. completion 2016-05 1 site Stand-alone
    Other conditions: Heart Transplantation
    View official trial listing →
  • Completed NCT NCT01556438

    Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

    Not yet reported Eli Lilly and Company 16 participants Est. completion 2015-08 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01568866

    Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

    Not yet reported Amgen 929 participants Est. completion 2018-02-05 241 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01594242

    Autophagy Induction After Bortezomib for Myeloma

    Not yet reported Abramson Cancer Center at Penn Medicine 11 participants Est. completion 2015-03-02 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01602224

    A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

    Not yet reported Eli Lilly and Company 220 participants Est. completion 2014-07 57 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01668719

    S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

    Not yet reported, Not yet reported SWOG Cancer Research Network 142 participants Est. completion 2025-09-22 417 sites Stand-alone
    Other conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01680796

    Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

    Not yet reported University of Florida Est. completion 2013-02 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01695330

    Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

    Not yet reported Oncotherapeutics 5 participants Est. completion 2015-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT01695941

    Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2027-03-03 4 sites Stand-alone
    Other conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01702831

    Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance

    Not yet reported University Health Network, Toronto 78 participants Est. completion 2022-07-31 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01706666

    Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

    Not yet reported Mayo Clinic 3 participants Est. completion 2016-05-17 4 sites Stand-alone
    Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01711528

    Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 41 participants Est. completion 2016-11-22 6 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT01720043

    Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients

    Not yet reported University of Utah 8 participants Est. completion 2017-07 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01720875

    Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

    Not yet reported University of Leeds 16 participants Est. completion 2018-08-29 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01729338

    Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

    Not yet reported Duke University 17 participants Est. completion 2016-12-31 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01734928

    Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

    Not yet reported Celgene 559 participants Est. completion 2022-05-13 321 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01736943

    Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

    Not yet reported Joseph Tuscano 25 participants Est. completion 2019-05-20 1 site Stand-alone
    Other conditions: Acute Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT01754389

    Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

    Not yet reported Dana-Farber Cancer Institute 138 participants Est. completion 2016-11 4 sites Stand-alone
    Other conditions: Graft Versus Host Disease
    View official trial listing →
  • Terminated NCT NCT01769443

    Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 2 participants Est. completion 2014-07 14 sites Stand-alone
    Other conditions: Primary Heart Transplant, Heart Transplantation, Heart Transplant
    View official trial listing →
  • Completed NCT NCT01782963

    Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)

    Not yet reported Massachusetts General Hospital 50 participants Est. completion 2017-12 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01805557

    Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

    Not yet reported, Not yet reported Fondazione Italiana Linfomi - ETS 108 participants Est. completion 2020-11-20 24 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
    View official trial listing →
  • Status unknown NCT NCT01812096

    Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 20 participants Est. completion 2017-06 1 site Stand-alone
    Other conditions: Multiple Myeloma Proved by Laboratory Tests
    View official trial listing →
  • Completed NCT NCT01830465

    VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

    Not yet reported Gruppo Italiano Studio Linfomi 45 participants Est. completion 2011-05 1 site Stand-alone
    Other conditions: Non Hodgkin's Follicular Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01842074

    Desensitization With Bortezomib Before a Living Kidney Donation

    Not yet reported Assistance Publique - Hôpitaux de Paris 10 participants Est. completion 2018-03 1 site Stand-alone
    Other conditions: Patients Awaiting a Living Kidney Donation
    View official trial listing →
  • Completed NCT NCT01848132

    Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

    Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 121 participants Est. completion 2018-08 21 sites Stand-alone
    Other conditions: Diffuse, Large B-Cell, Lymphoma
    View official trial listing →
  • Completed NCT NCT01873157

    Bortezomib in Late Antibody-mediated Kidney Transplant Rejection

    Not yet reported Medical University of Vienna 44 participants Est. completion 2017-02-28 1 site
    Other conditions: Late Rejection of Renal Transplant, Antibody-mediated Rejection
    View official trial listing →
  • Terminated NCT NCT01902862

    An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma

    Not yet reported Janssen-Cilag G.m.b.H 7 participants Est. completion 2007-08 3 sites Stand-alone
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Completed NCT NCT01910987

    Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib

    Not yet reported Janssen-Cilag International NV 80 participants Est. completion 2016-02 54 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01913730

    Maintenance Therapy With Subcutaneous Bortezomib

    Not yet reported European Myeloma Network B.V. 63 participants Est. completion 2023-09-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01916252

    Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

    Not yet reported PETHEMA Foundation 460 participants Est. completion 2016-11-16 74 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01954784

    Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

    Not yet reported Case Comprehensive Cancer Center 8 participants Est. completion 2017-01-30 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01965353

    A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 21 participants Est. completion 2021-09 4 sites Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Completed NCT NCT01998971

    A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 240 participants Est. completion 2024-01-11 22 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02026505

    Evaluation of Cardiotoxic Effects of Bortezomib

    Oregon Health and Science University 11 participants Est. completion 2019-03-01
    Heart failure Other conditions: Multiple Myeloma, Cardiotoxins
    View official trial listing →
  • Withdrawn NCT NCT02082405

    Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma

    Not yet reported Case Comprehensive Cancer Center Stand-alone
    Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02086942

    Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.

    Not yet reported Yongping Zhai 94 participants Est. completion 2017-08 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02093910

    Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy

    Not yet reported Sun Yat-sen University 100 participants Est. completion 2018-04 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02102594

    Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

    Not yet reported Charite University, Berlin, Germany 11 participants Est. completion 2019-08-30 2 sites Stand-alone
    Other conditions: Myasthenia Gravis, Systemic Lupus Erythematosus, Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT02136134

    Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 498 participants Est. completion 2024-01-10 105 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02145598

    Treatment Optimization in Patients With Untreated Multiple Myeloma

    Not yet reported, Not yet reported Dr. med. Lars-Olof Muegge 85 participants Est. completion 2018-12-31 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02188368

    Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

    Not yet reported Oncotherapeutics 45 participants Est. completion 2020-10-23 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02188537

    Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

    Not yet reported Swiss Cancer Institute 34 participants Est. completion 2018-04-17 12 sites Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT02195479

    A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 706 participants Est. completion 2024-08-07 160 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02211755

    Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

    Not yet reported National Cancer Institute (NCI) 28 participants Est. completion 2025-08-15 1 site Stand-alone
    Other conditions: Neoplasms, Myelodysplastic Syndromes, Lymphomas
    View official trial listing →
  • Completed NCT NCT02220049

    Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 18 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Advanced or Metastatic Solid Tumors
    View official trial listing →
  • Completed NCT NCT02220608

    Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma

    Not yet reported Washington University School of Medicine 10 participants Est. completion 2016-11-30 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02265510

    An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

    Not yet reported, Not yet reported Incyte Corporation 83 participants Est. completion 2019-02-27 14 sites Stand-alone
    Other conditions: Solid Tumors, Advanced Malignancies, Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT02268890

    A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

    Not yet reported Johnson & Johnson Taiwan Ltd 18 participants Est. completion 2015-07 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02290431

    Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Novartis Pharmaceuticals 31 participants Est. completion 2018-12-25 20 sites Stand-alone
    Other conditions: Relapse/Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02308280

    Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

    Not yet reported Maisonneuve-Rosemont Hospital 40 participants Est. completion 2023-09-27 1 site Stand-alone
    Other conditions: Multiple Myeloma, High-Risk Cancer
    View official trial listing →
  • Completed NCT NCT02336815

    Selinexor Treatment of Refractory Myeloma

    Not yet reported Karyopharm Therapeutics Inc 202 participants Est. completion 2019-07-26 61 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02351427

    Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation

    Not yet reported Asan Medical Center 30 participants Est. completion 2015-12 1 site
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT02352558

    A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

    Not yet reported Sumitomo Pharma America, Inc. 15 participants Est. completion 2019-05-16 8 sites Stand-alone
    Other conditions: Hematologic Malignancy
    View official trial listing →
  • Terminated NCT NCT02353468

    Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

    Not yet reported University of Colorado, Denver 3 participants Est. completion 2011-10 1 site Stand-alone
    Other conditions: Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT02353572

    Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Not yet reported, Not yet reported University of Colorado, Denver 3 participants Est. completion 2011-09 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
    View official trial listing →
  • Status unknown NCT NCT02362165

    CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

    Not yet reported Sun Yat-sen University 236 participants Est. completion 2018-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02424851

    Optimising Renal Outcome in Myeloma Renal Failure

    Not yet reported Oxford University Hospitals NHS Trust 31 participants Est. completion 2020-04-20 9 sites
    Chronic kidney disease Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02440464

    Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 57 participants Est. completion 2020-10-01 15 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02441686

    Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 46 participants Est. completion 2025-10 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02467010

    Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance

    Not yet reported University Medical Center Groningen 73 participants Est. completion 2013-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02474563

    Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

    Janssen Korea, Ltd., Korea 171 participants Est. completion 2014-05 18 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02500251

    Belimumab Impacting Transplant Eligibility

    Not yet reported, Not yet reported E. Steve Woodle 11 participants Est. completion 2018-08 2 sites Stand-alone
    Other conditions: Renal Transplant Rejection
    View official trial listing →
  • Terminated NCT NCT02518750

    Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

    Not yet reported St. Jude Children's Research Hospital 3 participants Est. completion 2018-03-11 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
    View official trial listing →
  • Status unknown NCT NCT02522572

    Quantitating the Impact of Plerixafor

    Not yet reported, Not yet reported E. Steve Woodle 12 participants Est. completion 2020-10 2 sites Stand-alone
    Other conditions: Transplants and Implants
    View official trial listing →
  • Status unknown NCT NCT02525172

    Immune Modulation Therapy for Pompe Disease

    Not yet reported National Taiwan University Hospital 8 participants Est. completion 2020-07 1 site Stand-alone
    Other conditions: Pompe Disease
    View official trial listing →
  • Completed NCT NCT02541383

    A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

    Not yet reported Intergroupe Francophone du Myelome 1085 participants Est. completion 2023-09-01 107 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02551718

    High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

    Not yet reported University of Washington 34 participants Est. completion 2021-05-13 1 site Stand-alone
    Other conditions: Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
    View official trial listing →
  • Status unknown NCT NCT02577783

    PDD vs PAD to Treat Initially Diagnosed MM

    Not yet reported The First Affiliated Hospital of Soochow University 64 participants Est. completion 2021-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02613598

    Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

    Not yet reported University of Michigan Rogel Cancer Center 15 participants Est. completion 2021-06-07 1 site Stand-alone
    Other conditions: Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT02654990

    Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

    Not yet reported pharmaand GmbH 248 participants Est. completion 2022-08-15 80 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • No Longer Available NCT NCT02666209

    Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

    Dana-Farber Cancer Institute 1 site
    Other conditions: Multiple Myeloma in Relapse, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02703779

    Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

    Not yet reported Siddhartha Ganguly 101 participants Est. completion 2020-04-08 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT02773030

    A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

    Not yet reported, Not yet reported Celgene 466 participants Est. completion 2028-07-28 162 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02783625

    Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

    Not yet reported Memorial Sloan Kettering Cancer Center 114 participants Est. completion 2026-04-21 11 sites Stand-alone
    Other conditions: Lymphoma, Relapsed/Refractory T-cell Lymphomas
    View official trial listing →
  • Completed NCT NCT02788201

    Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

    Not yet reported National Cancer Institute (NCI) 8 participants Est. completion 2019-10-23 1 site Stand-alone
    Other conditions: Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
    View official trial listing →
  • Status unknown NCT NCT02797041

    Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.

    IRCCS Centro di Riferimento Oncologico della Basilicata 100 participants Est. completion 2016-06
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02858999

    Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70

    Not yet reported Centre Hospitalier Universitaire, Amiens 40 participants Est. completion 2016-09 18 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02877082

    Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

    Not yet reported Emory University 5 participants Est. completion 2017-07 1 site Stand-alone
    Other conditions: Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT02893111

    Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder

    Not yet reported Tianjin Medical University General Hospital 5 participants Est. completion 2017-01-31 1 site Stand-alone
    Other conditions: Neuromyelitis Optica Spectrum Disorder
    View official trial listing →
  • Completed NCT NCT02951819

    A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

    Not yet reported Janssen Scientific Affairs, LLC 101 participants Est. completion 2020-08-17 26 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02971982

    PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 40 participants Est. completion 2018-12 1 site
    Other conditions: Treatment
    View official trial listing →
  • Status unknown NCT NCT02976272

    Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple

    University Hospital, Clermont-Ferrand 60 participants Est. completion 2021-01-31 1 site
    Other conditions: Multiple Myeloma, Bortezomib Regimen, Adult
    View official trial listing →
  • Status unknown NCT NCT02981199

    Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients

    Not yet reported Chen Wenming 80 participants Est. completion 2019-12 1 site
    Other conditions: Microtransplantation, Autologous Stem Cell Transplantation, Multiple Myeloma in Relapse
    View official trial listing →
  • Withdrawn NCT NCT03000634

    2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy

    Not yet reported University of Arkansas Est. completion 2017-04-01 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03013114

    A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)

    Not yet reported Shandong University 20 participants Est. completion 2017-12 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT03044353

    Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

    Not yet reported GlaxoSmithKline 7 participants Est. completion 2019-01-03 3 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Status unknown NCT NCT03089411

    Collection of Additional Data Followed the Study IFM 2013-04

    Nantes University Hospital 340 participants Est. completion 2017-07-15 63 sites
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Status unknown NCT NCT03103555

    Treatment of Adult-Onset Immunodeficiency With Bortezomib

    Not yet reported Mahidol University 5 participants Est. completion 2019-11-01 1 site Stand-alone
    Other conditions: Adult-onset Immunodeficiency
    View official trial listing →
  • Completed NCT NCT03110562

    Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

    Not yet reported Karyopharm Therapeutics Inc 402 participants Est. completion 2022-05-12 157 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03117361

    Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

    Not yet reported PharmaMar 10 participants Est. completion 2018-07-30 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03136653

    A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

    Not yet reported, Not yet reported Molecular Partners AG 33 participants Est. completion 2021-01-13 24 sites Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Withdrawn NCT NCT03168100

    2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

    Not yet reported University of Arkansas Est. completion 2019-01-24 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03188172

    MUK Nine b: OPTIMUM Treatment Protocol

    Not yet reported University of Leeds 95 participants Est. completion 2026-05-31 21 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03210753

    Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma

    National Taiwan University Hospital 400 participants Est. completion 2020-07 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03217812

    A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

    Not yet reported Janssen Research & Development, LLC 220 participants Est. completion 2024-03-08 44 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03242460

    The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

    Not yet reported Kosin University Gospel Hospital 55 participants Est. completion 2019-05-02 1 site
    Other conditions: Relapsed and/or refractorY Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03314181

    A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported AbbVie 156 participants Est. completion 2031-05 40 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03319667

    A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not yet reported Sanofi 475 participants Est. completion 2027-06-30 104 sites Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Status unknown NCT NCT03335098

    Study of VTD in Waldenstrom's Macroglobulinemia

    Not yet reported Seoul National University Hospital 15 participants Est. completion 2020-12 2 sites Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03390387

    Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

    Not yet reported Federal Research Institute of Pediatric Hematology, Oncology and Immunology 4000 participants Est. completion 2025-11 58 sites Stand-alone
    Other conditions: Childhood Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT03412565

    A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

    Not yet reported Janssen Research & Development, LLC 265 participants Est. completion 2024-04-18 64 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03443570

    Rituximab Combining Bortezomib Versus Rituximab in Management of ITP

    Not yet reported Shandong University 200 participants Est. completion 2021-03-01 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT03487133

    Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma

    Not yet reported Samsung Medical Center 32 participants Est. completion 2020-09-30 1 site Stand-alone
    Other conditions: Relapsed and/or Refractory Cutaneous T-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03493737

    Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma

    Central Hospital, Nancy, France 43 participants Est. completion 2020-02-15 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03544281

    To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported, Not yet reported GlaxoSmithKline 153 participants Est. completion 2024-02-28 26 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT03591744

    Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

    Not yet reported City of Hope Medical Center Est. completion 2019-10-25 5 sites Stand-alone
    Other conditions: Plasma Cell Leukemia
    View official trial listing →
  • Completed NCT NCT03652064

    A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

    Not yet reported Janssen Research & Development, LLC 395 participants Est. completion 2026-04-21 114 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03700229

    Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

    Not yet reported Peking Union Medical College Hospital 22 participants Est. completion 2020-04-15 1 site Stand-alone
    Other conditions: Acquired Hemophilia A
    View official trial listing →
  • Withdrawn NCT NCT03701321

    Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported National Cancer Institute (NCI) Est. completion 2020-05-28 3 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03710603

    Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

    Not yet reported Stichting European Myeloma Network 709 participants Est. completion 2029-11 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Available NCT NCT03763370

    Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

    GlaxoSmithKline
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03828292

    An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

    Not yet reported GlaxoSmithKline 15 participants Est. completion 2024-09-05 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03870451

    Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

    Not yet reported Wake Forest University Health Sciences 18 participants Est. completion 2023-02-10 1 site Stand-alone
    Other conditions: Chemotherapy-induced Peripheral Neuropathy, Plasma Cell Myeloma
    View official trial listing →
  • Status unknown NCT NCT03908138

    RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma

    Not yet reported Shandong Provincial Hospital 120 participants Est. completion 2022-12-31 1 site
    Other conditions: Hematologic Neoplasms, Multiple Myeloma, Efficacy, Safety
    View official trial listing →
  • Status unknown NCT NCT03982771

    BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

    Not yet reported Peking Union Medical College Hospital 30 participants Est. completion 2023-01-01 1 site Stand-alone
    Other conditions: Idiopathic Multicentric Castleman's Disease
    View official trial listing →
  • Active, not recruiting NCT NCT03989414

    A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

    Not yet reported, Not yet reported Celgene 424 participants Est. completion 2026-11-30 49 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04008888

    a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 50 participants Est. completion 2020-08-01 1 site Stand-alone
    Other conditions: Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Plasmacytoma, Loss of Chromosome 17p, t(14;16), t(4;14), T(14;20), 1Q21 Amplification, Complex Karyotype
    View official trial listing →
  • Active, not recruiting NCT NCT04052880

    Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

    Not yet reported Larysa Sanchez 17 participants Est. completion 2026-05 1 site Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04083014

    Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

    Not yet reported Peking Union Medical College Hospital 33 participants Est. completion 2024-03-20 1 site Stand-alone
    Other conditions: Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
    View official trial listing →
  • Active, not recruiting NCT NCT04091126

    Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

    Not yet reported GlaxoSmithKline 118 participants Est. completion 2026-12-31 30 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04131309

    A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

    Not yet reported Stichting European Myeloma Network 40 participants Est. completion 2025-01-27 5 sites Stand-alone
    Other conditions: Light Chain (AL) Amyloidosis, Stage 3B
    View official trial listing →
  • Active, not recruiting NCT NCT04140162

    Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

    Not yet reported University of Michigan Rogel Cancer Center 57 participants Est. completion 2026-09-02 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04151615

    VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma

    Boryung Pharmaceutical Co., Ltd 203 participants Est. completion 2023-01-11 24 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04181827

    A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 419 participants Est. completion 2027-03-31 88 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Enrolling by invitation NCT NCT04210791

    Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

    Nanjing University School of Medicine 500 participants Est. completion 2030-12-31 1 site
    Other conditions: AL Amyloidosis, Plasma Cell Dyscrasia
    View official trial listing →
  • Completed NCT NCT04224571

    CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

    Not yet reported Chinese University of Hong Kong 208 participants Est. completion 2023-02-15 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, in Relapse
    View official trial listing →
  • Active, not recruiting NCT NCT04268498

    A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

    Not yet reported University of Miami 310 participants Est. completion 2027-02-01 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04285268

    Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not yet reported Rutgers, The State University of New Jersey Est. completion 2024-09-30 1 site Stand-alone
    Other conditions: High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
    View official trial listing →
  • Completed NCT NCT04309942

    Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment

    Not yet reported Centre Hospitalier Universitaire de Nīmes 60 participants Est. completion 2023-05-30 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04348006

    Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

    Not yet reported Al-Rasheed University College Est. completion 2021-07-30 1 site Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04352205

    Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

    Not yet reported Emory University 17 participants Est. completion 2024-01-19 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma, Renal Failure
    View official trial listing →
  • Active, not recruiting NCT NCT04512235

    A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

    Not yet reported Alexion Pharmaceuticals, Inc. 281 participants Est. completion 2027-04-08 110 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Terminated NCT NCT04570631

    Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported AbbVie 4 participants Est. completion 2025-05-05 19 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04656951

    Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

    Not yet reported University of Cologne 67 participants Est. completion 2031-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04722146

    A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 140 participants Est. completion 2027-10-13 27 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04754945

    Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

    Not yet reported Emory University 11 participants Est. completion 2028-07-24 6 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Withdrawn NCT NCT04776850

    Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

    Not yet reported M.D. Anderson Cancer Center Est. completion 2022-12-05 Stand-alone
    Other conditions: Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia, Sickle Beta Thalassemia, Sickle Cell Disease, Sickle Cell-SS Disease
    View official trial listing →
  • Active, not recruiting NCT NCT04786028

    A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

    Not yet reported Canadian Myeloma Research Group 72 participants Est. completion 2027-06 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04912427

    Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

    Not yet reported Washington University School of Medicine 1 participants Est. completion 2024-01-26 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04923893

    A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

    Not yet reported Janssen Research & Development, LLC 743 participants Est. completion 2036-09-22 136 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04956302

    Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

    Not yet reported Abdullah Khan 1 participants Est. completion 2022-06-16 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04975997

    Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Not yet reported Celgene 939 participants Est. completion 2032-06-25 259 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05123131

    Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Cancer Trials Ireland 54 participants Est. completion 2027-12-15 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05147493

    A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

    Not yet reported Hellenic Society of Hematology 51 participants Est. completion 2025-02 6 sites Stand-alone
    Other conditions: Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases
    View official trial listing →
  • Status unknown NCT NCT05218603

    Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

    PETHEMA Foundation 100 participants Est. completion 2025-11-06 32 sites
    Other conditions: Multiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT)
    View official trial listing →
  • Active, not recruiting NCT NCT05231629

    Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

    Not yet reported University of Alabama at Birmingham 300 participants Est. completion 2029-12 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05250973

    A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

    Not yet reported Janssen Research & Development, LLC 151 participants Est. completion 2026-11-23 46 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Withdrawn NCT NCT05293509

    Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

    Not yet reported M.D. Anderson Cancer Center Est. completion 2023-09-18 1 site Stand-alone
    Other conditions: Stem Cell Transplantation
    View official trial listing →
  • Status unknown NCT NCT05561049

    Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma

    The First Affiliated Hospital of Soochow University 120 participants Est. completion 2025-09-30
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05564052

    A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported Janssen Research & Development, LLC 36 participants Est. completion 2024-09-26 66 sites Stand-alone
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Active, not recruiting NCT NCT05849610

    Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

    Not yet reported PETHEMA Foundation 30 participants Est. completion 2029-07 10 sites Stand-alone
    Other conditions: High-Risk de Novo Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05889221

    Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

    Not yet reported Poitiers University Hospital 74 participants Est. completion 2028-09-01 1 site Stand-alone
    Other conditions: Multiple Myeloma, Myeloma Multiple, Myeloma
    View official trial listing →
  • Withdrawn NCT NCT05895201

    High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

    Not yet reported, Not yet reported Indiana University Est. completion 2025-12 1 site Stand-alone
    Other conditions: Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT05982756

    Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML

    Not yet reported Zhongnan Hospital 40 participants Est. completion 2023-12-01 1 site Stand-alone
    Other conditions: Bortezomib, Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT06169215

    Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 58 participants Est. completion 2027-09-23 27 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT06212596

    Selinexor, Cyclophosphamide and Prednisone in Myeloma

    Not yet reported University of Leeds 66 participants Est. completion 2023-11-14 13 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06215638

    An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

    Not yet reported Peking Union Medical College Hospital 30 participants Est. completion 2024-12-30 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Withdrawn NCT NCT06348147

    Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

    Not yet reported UNC Lineberger Comprehensive Cancer Center Est. completion 2029-05 1 site Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
    View official trial listing →
  • Active, not recruiting NCT NCT06413498

    A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

    Not yet reported Kite, A Gilead Company 452 participants Est. completion 2031-07 117 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06457464

    Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients

    Assiut University 100 participants Est. completion 2025-10-01
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06577025

    A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 43 participants Est. completion 2030-09-30 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06868667

    Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 24 participants Est. completion 2028-06-30 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06956170

    All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 21 participants Est. completion 2029-06-25 13 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07072585

    Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

    Not yet reported, Not yet reported Children's Oncology Group 1708 participants Est. completion 2035-09-01 Stand-alone
    Other conditions: Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07334535

    Isa-VRD in TIE HRMM

    Not yet reported Peking Union Medical College Hospital 117 participants Est. completion 2029-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07403071

    Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research

    The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 200 participants Est. completion 2027-12-31
    Other conditions: Multiple Myeloma, Peripheral Neuropathy Due to Chemotherapy
    View official trial listing →
  • Not yet recruiting NCT NCT07464210

    Nemtabrutinib, Bortezomib, and Rituximab for WM

    Not yet reported Seoul National University Hospital 19 participants Est. completion 2030-08-01 1 site Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia
    View official trial listing →
  • Not yet recruiting NCT NCT07635511

    Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies

    Not yet reported The First Affiliated Hospital of Soochow University 42 participants Est. completion 2029-05-31 Stand-alone
    Other conditions: Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies
    View official trial listing →
  • Not yet recruiting NCT NCT07637526

    Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma

    PETHEMA Foundation 100 participants Est. completion 2027-12-31
    Other conditions: Relapse Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT07689006

    Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens

    Bristol-Myers Squibb 341 participants Est. completion 2025-03-28 1 site
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07709715

    A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis

    Not yet reported Nexcella Inc. 260 participants Est. completion 2032-12
    Other conditions: Light Chain (AL) Amyloidosis
    View official trial listing →
  • Not yet recruiting NCT NCT07732712

    Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells

    Not yet reported, Not yet reported The Affiliated People's Hospital of Ningbo University 15 participants Est. completion 2028-12-01 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07793422

    Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis

    Not yet reported AbbVie 370 participants Est. completion 2034-12
    Other conditions: Amyloid Light Chain (AL) Amyloidosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.